Publications

5674 Results

Distant-Disease Free Interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;J Gralow;F Meric-Bernstam;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;E Alba;S Delaloge;M Martin;C Kelly;M Ruiz Borrego;M Gil-Gil;C Arce-Salinas;E Brain;E Lee;J-Y Pierga;B Bermejo;M Ramos Vazquez;K Jung;J-M Ferrero;A Schott;S Shak;P Sharma;D Lew;J Miao;D Tripathy;L Pusztai;G Hortobagyi
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 7-10, 2021, San Antonio, TX), oral slide presentation, #GS2-07
Year
2021
Research Committee(s)
Breast
Study Number(s)
S1007

Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Recurrence Score in node-positive postmenopausal breast cancer: results from an analysis in the SWOG S8814 trial

Authors
C Speers;WF Symmans;W Barlow;A Trevarton;S The;L Du;J Rae;S Shak;R Baehner;P Sharma;L Pusztai;G Hortobagyi;D Hayes;K Albain;A Godwin;A Thompson
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 7-10, 2021, San Antonio, TX), spotlight poster discussion, #PD9-06
Year
2021
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

SWOG S1931 (PROBE trial): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer

Authors
U Vaishampayan;C Tangen;A Tripathi;B Shuch;S Pal;P Barata;A Tan;P Zuckerman;E Mayerson;P Lara;N Agarwal;N Vogelzang;I Thompson;H Kim
Journal / Conference
Society of Urologic Oncology (Dec 1-3, 2021, Orlando, FL), poster
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1931

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Authors
L Muffly;J Yin;S Jacobson;A Advani;S Luger;M Tallman;M Litzow;R Larson;T Keegan;W Stock
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #337
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
C10403

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Authors
J Woyach;A Ruppert;G Perez;A Booth;D Feldman;E Dib;A Jatoi;J Le-Rademacher;N Heerema;G Lozanski;R Little;B Hill;W Ding;R Stone;S Mandrekar;J Byrd
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster, #3728
Year
2021
Research Committee(s)
Leukemia

Long term results of A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy

Authors
J Woyach;A Ruppert;N Heerema;W Zhao;A Booth;W Ding;N Bartlett;D Brander;P Barr;K Rogers;S Parikh;S Coutre;A Hurria;G Lozanski;S Nattam;R Larson;H Erba;M Litzow;C Owen;J Atkins;J Abramson;R Little;S Smith;R Stone;S Mandrekar;J Byrd
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #639
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
CTSU/A041202

Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Authors
D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;Kahl;J Song;M LeBlanc;S Smith;JW Friedberg;D Persky
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster presentation, #1423
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
S0014, S0313, S1001

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance 051701

Authors
J Abramson;A Ruppert;S Giri;A Hudson;E Hsi;R Little;S Gore;A Vallurupalli;D Landsburg;B Kahl;JW Friedberg;N Bartlett;J Leonard
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #523
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051701

Prediction Of Early Mortality With Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients From MRC/NCRI and SWOG

Authors
X Wang;I Thomas;C Ariti;M Dennis;P Mehta;N Russell;M Sydenham;R Hills;A Burnett;S Nand;S Assouline;L Michaelis;H Erba;K Kerr;R Walter;M Othus
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #220
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
S0432, S0703, S1612

Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Authors
A Tarhini;A Tan;I El Naqa;S Lee;F Hodi;L Butterfield;W LaFramboise;W Storkus;J Conejo-Garcia;P Hwu;H Streicher;V Sondak;J Kirkwood
Journal / Conference
Society for Immunotherapy of Cancer’s (SITC) Annual Meeting (Nov 10-14, 2021, Washington, DC), poster
Year
2021
Research Committee(s)
Melanoma
Study Number(s)
CTSU/E1609